GILEAD SCIENCES, INC. Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) of $47.51 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FutureAmortizationExpenseRemainderOfFiscalYear · last filed 2012-05-04
- GILEAD SCIENCES, INC. future amortization expense, remainder of fiscal year (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $47.51M.
- GILEAD SCIENCES, INC. future amortization expense, remainder of fiscal year (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$17.41M.
| Period end | Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) 3 month | Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) 6 month | Future Amortization Expense, Remainder of Fiscal Year (Deprecated 2012-01-31) 9 month |
|---|---|---|---|
| 2012-03-31 | $47.51M 10-Q · filed 2012-05-04 | ||
| 2011-09-30 | -$17.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $17.41M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $34.81M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |